Skip to main content

Table 3 Surgical variables and complications

From: Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer

Variable

Value

Patients with radical prostatectomy, n

30

Surgery hindered, n (%)

 

  Fibrosis

7 (23.3)

  Vulnerability

1 (3.3)

Surgery duration, min#

 

  Median (mean)

195 (208.7)

  Range

140-333

Nerve sparing, n (%)

 

  Bilateral

6 (20.0)

  Unilateral

3 (10.0)

  Not possible

21 (70.0)

Intraoperative blood loss, ml

 

  Median (mean)

600 (769.2)

  Range

100-2600

No. of transfused blood units, n

 

  Median (mean)

0 (0.9)

  Range

0-5

Complications, needing intervention, n (%)§

 

  Symptomatic pelvic hematoma

1 (3.3)

  Hydronephrosis

1 (3.3)

  Lymphocele

6 (20.0)

Complications in ≥ 10% of cases, n (%)§

 

  Joint pain

3 (10.0)

  Venous/pulmonary thromboembolism

5 (16.7)

Time to catheter removal, days

 

  Median (mean)

8 (13.1)

  Range

7-47

Continence, no. of pads, n (%)*

 

  0

29 (96.7)

  ≥1

1 (3.3)

Erectile function (n = 26), n (%)*

 

  Potent (E 3–4)

4 (15.4)

  Potent with erection aids (E 3–4)

3 (11.5)

  Tumescence (E 1–2)

5 (19.2)

  Impotence (E 0)

14 (53.9)

  1. Abbreviations: #skin incision to skin suture; §within 4 weeks from surgery; *after a median follow up of 48.6 months (range 14.1-87.8).